 Business Wire India Patients treated with the investigational combination of trifluridinetipiracil in combination with bevacizumab in the pivotal Phase 3 SUNLIGHT trial achieved clinically meaningful improvement in overall survival compared to trifluridinetipiracil alone Results demonstrate that trifluridinetipiracil plus bevacizumab may be an effective and well-tolerated therapy for patients with metastatic colorectal cancer following disease progression... The post Servier and Taiho Oncology... 